Chest Medicine | Page 32 of 170 | Links Medicus Content Curation & Alerts in Medicine

1/ HGE (https://t.co/VMUVMAo1bJ) position paper on #LongCOVID #PACS . By focusing on the most severe patients, w severe organ damage/dysfunction following mild/moderate #COVID19 – we will search for genetic and immunological mechanisms of disease https://t.co/dZQPEoNkhl pic.twitter.com/tgblk7oFQG

— Petter Brodin (@BrodinPetter) April 5, 2022

Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.

6 Apr, 2022 | 10:59h | UTC

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel – New England Journal of Medicine

Commentary: Mixed Bag for Fourth Dose of Pfizer Vaccine vs Omicron— Real-world data show less infection and severity, but long-term benefit less clear – MedPage Today (free registration required)

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

Commentary on Twitter

Just published @NEJM
4th dose vaccine protection in >620,000 people vs 3-doses in >620,000, all age 60+, Omicron wave, Israel
—4-fold lower rate of severe disease, no waning at 6 weeks
—2-fold lower rate of infection, rapidly wanedhttps://t.co/g8uGMXGHD6 pic.twitter.com/D7WHywTI1j

— Eric Topol (@EricTopol) April 5, 2022

M-A: Risk of recurrence in women with venous thromboembolism related to estrogen-containing contraceptives.

6 Apr, 2022 | 10:55h | UTC

Risk of recurrence in women with venous thromboembolism related to estrogen-containing contraceptives: Systematic review and meta-analysis – Journal of Thrombosis and Haemostasis

Review and M-A: pulmonary rehabilitation for Post-Covid.

6 Apr, 2022 | 10:42h | UTC

Study 1: The effectiveness of pulmonary rehabilitation for Post-COVID symptoms: A rapid review of the literature – Respiratory Medicine

Study 2: Effect of Pulmonary Rehabilitation for Patients With Post-COVID-19: A Systematic Review and Meta-Analysis – Frontiers in Medicine

Billions of people still breathe unhealthy air: new WHO data.

5 Apr, 2022 | 09:59h | UTC

News Release: Billions of people still breathe unhealthy air: new WHO data – World Health Organization

Report: WHO Air quality Database 2022

Commentaries:

South-East Asia, Africa and Middle East are World’s Air Pollution Hot Spots in WHO’s Largest-Ever Data Release – Health Policy Watch

WHO says 99% of world’s population breathes poor-quality air – Associated Press

Commentary on Twitter (thread – click for more)

Shocking!
99% – or almost the entire world's population breathes air with unhealthy levels of fine particulate matter & nitrogen dioxide, and threatens their health.
More: https://t.co/Llaj2wHk0V #HealthierTomorrow pic.twitter.com/QlHUP4iyS4

— World Health Organization (WHO) (@WHO) April 4, 2022

Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.

5 Apr, 2022 | 09:46h | UTC

The Evidence On 4th Doses of Covid Vaccines & the Thorny Question of Age Thresholds – Absolutely Maybe Blog, by Hilda Bastian

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

Commentary on Twitter

https://twitter.com/hildabast/status/1509724907965665280

RCT: Routine lung volume recruitment is not beneficial for boys with Duchenne muscular dystrophy.

5 Apr, 2022 | 08:04h | UTC

Routine lung volume recruitment in boys with Duchenne muscular dystrophy: a randomised clinical trial – Thorax

Two new studies show vaccination provides additional protection after Covid-19 infection.

4 Apr, 2022 | 01:16h | UTC

Study 1: Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden – The Lancet Infectious Diseases

Study 2: Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study – The Lancet Infectious Diseases

Commentaries:

Interplay of infection and vaccination in long-term protection from COVID-19 – The Lancet Infectious Diseases

Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world – The Lancet Infectious Diseases

Vaccines offer substantial extra protection after COVID-19 infection – CIDRAP

Had COVID? Getting Vaccine Boosts Resilience Even More, Studies Show – HealthDay

Retrospective cohort study: Pfizer vaccine reduces the risk of reinfection after recovery from Covid-19.

Cohort study: Protection against SARS-CoV-2 after Covid-19 vaccination lasts longer in patients with previous infection.

Commentary on Twitter (thread – click for more)

THREAD | New studies in @TheLancetInfDis confirm #COVID19 vaccines provide extra protection for those with immunity from previous infection, especially against severe disease ⤵️

(Cases of reinfection from omicron variants not included)

— The Lancet (@TheLancet) April 1, 2022

Still coughing after COVID? Here’s why it happens and what to do about it.

1 Apr, 2022 | 09:50h | UTC

Still coughing after COVID? Here’s why it happens and what to do about it – The Conversation

Review: Predicting the course of asthma from childhood until early adulthood.

1 Apr, 2022 | 08:32h | UTC

Predicting the course of asthma from childhood until early adulthood – Current Opinion in Allergy and Clinical Immunology

State-of-the-art review of lung imaging in cystic fibrosis with recommendations for pulmonologists and radiologists.

1 Apr, 2022 | 08:19h | UTC

State-of-the-art review of lung imaging in cystic fibrosis with recommendations for pulmonologists and radiologists from the “iMAging managEment of cySTic fibROsis” (MAESTRO) consortium – European Respiratory Review

Practice review: Evidence-based management approaches for patients with severe chronic obstructive pulmonary disease (COPD).

1 Apr, 2022 | 08:29h | UTC

Evidence-based management approaches for patients with severe chronic obstructive pulmonary disease (COPD): A practice review – Palliative Medicine

RCT: Early treatment with ivermectin does not improve outcomes in patients with Covid-19.

31 Mar, 2022 | 08:41h | UTC

Effect of Early Treatment with Ivermectin among Patients with Covid-19- New England Journal of Medicine

Commentary: Ivermectin does not prevent COVID-19 hospitalization, a new study says – NPR

Commentary on Twitter

Ivermectin: the largest randomized, double-blind trial yet conducted, with early treatment, indicates there is no difference compared with placebo. It doesn't work. Period. https://t.co/wiFygjRgkk
just published @NEJM pic.twitter.com/uZ0mMZnO0E

— Eric Topol (@EricTopol) March 30, 2022

RCT: Early outpatient treatment with convalescent plasma reduces the risk of hospitalization in patients with Covid-19.

31 Mar, 2022 | 08:39h | UTC

Early Outpatient Treatment for Covid-19 with Convalescent Plasma – New England Journal of Medicine

Commentaries:

Study finds convalescent plasma can be effective early COVID-19 therapy – Johns Hopkins University School of Medicine

Early Use of High-Titer Plasma Reduced COVID Hospitalizations— Randomized trial that influenced indication shows benefits in a mostly unvaccinated population – MedPage Today (free registration required)

Commentary on Twitter

https://twitter.com/NEJM/status/1509278140433981444

USPSTF Draft Recommendation Statement: the current evidence is insufficient to recommend screening for obstructive sleep apnea in asymptomatic individuals.

31 Mar, 2022 | 08:42h | UTC

Draft Recommendation Statement: Obstructive Sleep Apnea in Adults: Screening – US Preventive Services Task Force

Commentary: USPSTF: Evidence Lacking for OSA Screening in Asymptomatic Adults – HealthDay

A Narrative Review on the approach to antimicrobial use in ventilated patients with multidrug resistant organisms in respiratory samples—to treat or not to treat?

31 Mar, 2022 | 08:27h | UTC

A Narrative Review on the Approach to Antimicrobial Use in Ventilated Patients with Multidrug Resistant Organisms in Respiratory Samples—To Treat or Not to Treat? That Is the Question – Antibiotics

Commentary on Twitter

https://twitter.com/ABsteward/status/1508917245740818438

Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study.

31 Mar, 2022 | 08:23h | UTC

Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study – The BMJ

Editorial: Screening high risk populations for lung cancer

News Release: US lung cancer screening linked to earlier diagnosis and better survival – British Medical Journal

Screening for Lung Cancer: CHEST Guideline and Expert Panel Report.

USPSTF Statement: begin screening for lung cancer at age 50 years instead of 55 years for patients at risk

Meta-analysis: Lung cancer screening using low-dose computed tomography reduces lung cancer–specific mortality, albeit with a tradeoff of likely overdiagnosis

Commentary on Twitter

Increases in the early detection of lung cancer since 2014 in the US have saved an estimated 10,100 lives, but screening rates are still extremely low and disparities in access to lung cancer screening continue to exist, say researchers https://t.co/j58LfcGCKU

— The BMJ (@bmj_latest) March 31, 2022